A

ALX Oncology Holdings

D
ALXO
USD
-0.003
(-0.197%)
Market Closed
41,744.00
حجم التداول
-2.425
الربح لكل سهم
-
العائد الربحي
-0.425824
P/E
80,061,120.80
حجم السوق
اليوم
-0.1970%
1 اسبوع
5.923%
1 شهر
-4.403%
6 اشهر
-91.334%
12 اشهر
-83.333%
بداية السنة
-89.792%
كل الوقت
0%

Title:
ALX Oncology Holdings

Sector:
Healthcare
Industry:
Biotechnology
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
هل تحتاج مساعدة او لديك استفسار؟